PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice

Javier O. Valenzuela, Cristina Iclozan, Mohammad S. Hossain, Martin Prlic, Emily Hopewell, Crystina C. Bronk, Junmei Wang, Esteban Celis, Robert W. Engelman, Bruce R. Blazar, Michael J. Bevan, Edmund K. Waller, Xue Zhong Yu, Amer A. Beg

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

When used as therapy for hematopoietic malignancies, allogeneic BM transplantation (BMT) relies on the graftversus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms. However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. To enhance the therapeutic potential of BMT, we sought to find therapeutic targets that could inhibit GVHD while preserving GVL and immune responses to infectious agents. We show here that T cell responses triggered in mice by either Listeria monocytogenes or administration of antigen and adjuvant were relatively well preserved in the absence of PKC isoform θ (PKCθ), a key regulator of TCR signaling. In contrast, PKCθ was required for alloreactivity and GVHD induction. Furthermore, absence of PKCθ raised the threshold for T cell activation, which selectively affected alloresponses. Most importantly, PKCθ-deficient T cells retained the ability to respond to virus infection and to induce GVL effect after BMT. These findings suggest PKCθ is a potentially unique therapeutic target required for GVHD induction but not for GVL or protective responses to infectious agents.

Original languageEnglish (US)
Pages (from-to)3774-3786
Number of pages13
JournalJournal of Clinical Investigation
Volume119
Issue number12
DOIs
StatePublished - Dec 1 2009

Fingerprint

Graft vs Host Disease
Leukemia
T-Lymphocytes
Homologous Transplantation
Infection
Transplantation
Minor Histocompatibility Antigens
Residual Neoplasm
Listeria monocytogenes
Virus Diseases
Hematologic Neoplasms
Therapeutics
Protein Isoforms
Epithelium
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Valenzuela, J. O., Iclozan, C., Hossain, M. S., Prlic, M., Hopewell, E., Bronk, C. C., ... Beg, A. A. (2009). PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. Journal of Clinical Investigation, 119(12), 3774-3786. https://doi.org/10.1172/JCI39692

PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. / Valenzuela, Javier O.; Iclozan, Cristina; Hossain, Mohammad S.; Prlic, Martin; Hopewell, Emily; Bronk, Crystina C.; Wang, Junmei; Celis, Esteban; Engelman, Robert W.; Blazar, Bruce R.; Bevan, Michael J.; Waller, Edmund K.; Yu, Xue Zhong; Beg, Amer A.

In: Journal of Clinical Investigation, Vol. 119, No. 12, 01.12.2009, p. 3774-3786.

Research output: Contribution to journalArticle

Valenzuela, JO, Iclozan, C, Hossain, MS, Prlic, M, Hopewell, E, Bronk, CC, Wang, J, Celis, E, Engelman, RW, Blazar, BR, Bevan, MJ, Waller, EK, Yu, XZ & Beg, AA 2009, 'PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice', Journal of Clinical Investigation, vol. 119, no. 12, pp. 3774-3786. https://doi.org/10.1172/JCI39692
Valenzuela, Javier O. ; Iclozan, Cristina ; Hossain, Mohammad S. ; Prlic, Martin ; Hopewell, Emily ; Bronk, Crystina C. ; Wang, Junmei ; Celis, Esteban ; Engelman, Robert W. ; Blazar, Bruce R. ; Bevan, Michael J. ; Waller, Edmund K. ; Yu, Xue Zhong ; Beg, Amer A. / PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 12. pp. 3774-3786.
@article{23a0be7c4f6f4fd6a7726b58df0ce77a,
title = "PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice",
abstract = "When used as therapy for hematopoietic malignancies, allogeneic BM transplantation (BMT) relies on the graftversus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms. However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. To enhance the therapeutic potential of BMT, we sought to find therapeutic targets that could inhibit GVHD while preserving GVL and immune responses to infectious agents. We show here that T cell responses triggered in mice by either Listeria monocytogenes or administration of antigen and adjuvant were relatively well preserved in the absence of PKC isoform θ (PKCθ), a key regulator of TCR signaling. In contrast, PKCθ was required for alloreactivity and GVHD induction. Furthermore, absence of PKCθ raised the threshold for T cell activation, which selectively affected alloresponses. Most importantly, PKCθ-deficient T cells retained the ability to respond to virus infection and to induce GVL effect after BMT. These findings suggest PKCθ is a potentially unique therapeutic target required for GVHD induction but not for GVL or protective responses to infectious agents.",
author = "Valenzuela, {Javier O.} and Cristina Iclozan and Hossain, {Mohammad S.} and Martin Prlic and Emily Hopewell and Bronk, {Crystina C.} and Junmei Wang and Esteban Celis and Engelman, {Robert W.} and Blazar, {Bruce R.} and Bevan, {Michael J.} and Waller, {Edmund K.} and Yu, {Xue Zhong} and Beg, {Amer A.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1172/JCI39692",
language = "English (US)",
volume = "119",
pages = "3774--3786",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice

AU - Valenzuela, Javier O.

AU - Iclozan, Cristina

AU - Hossain, Mohammad S.

AU - Prlic, Martin

AU - Hopewell, Emily

AU - Bronk, Crystina C.

AU - Wang, Junmei

AU - Celis, Esteban

AU - Engelman, Robert W.

AU - Blazar, Bruce R.

AU - Bevan, Michael J.

AU - Waller, Edmund K.

AU - Yu, Xue Zhong

AU - Beg, Amer A.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - When used as therapy for hematopoietic malignancies, allogeneic BM transplantation (BMT) relies on the graftversus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms. However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. To enhance the therapeutic potential of BMT, we sought to find therapeutic targets that could inhibit GVHD while preserving GVL and immune responses to infectious agents. We show here that T cell responses triggered in mice by either Listeria monocytogenes or administration of antigen and adjuvant were relatively well preserved in the absence of PKC isoform θ (PKCθ), a key regulator of TCR signaling. In contrast, PKCθ was required for alloreactivity and GVHD induction. Furthermore, absence of PKCθ raised the threshold for T cell activation, which selectively affected alloresponses. Most importantly, PKCθ-deficient T cells retained the ability to respond to virus infection and to induce GVL effect after BMT. These findings suggest PKCθ is a potentially unique therapeutic target required for GVHD induction but not for GVL or protective responses to infectious agents.

AB - When used as therapy for hematopoietic malignancies, allogeneic BM transplantation (BMT) relies on the graftversus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms. However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. To enhance the therapeutic potential of BMT, we sought to find therapeutic targets that could inhibit GVHD while preserving GVL and immune responses to infectious agents. We show here that T cell responses triggered in mice by either Listeria monocytogenes or administration of antigen and adjuvant were relatively well preserved in the absence of PKC isoform θ (PKCθ), a key regulator of TCR signaling. In contrast, PKCθ was required for alloreactivity and GVHD induction. Furthermore, absence of PKCθ raised the threshold for T cell activation, which selectively affected alloresponses. Most importantly, PKCθ-deficient T cells retained the ability to respond to virus infection and to induce GVL effect after BMT. These findings suggest PKCθ is a potentially unique therapeutic target required for GVHD induction but not for GVL or protective responses to infectious agents.

UR - http://www.scopus.com/inward/record.url?scp=72849123229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849123229&partnerID=8YFLogxK

U2 - 10.1172/JCI39692

DO - 10.1172/JCI39692

M3 - Article

VL - 119

SP - 3774

EP - 3786

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -